GlassScriptPhysician profile
Fiona K Pakonis
NPI 1821163643
$928.37
in general payments reported to CMS, 2019-2025
13 companies · $215 in 2025
The $215 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.81 · 2020: $29.61 · 2021: $67.28 · 2022: $96.86 · 2023: $188 · 2024: $304 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $242.64 | 2021-2025 | Qelbree, Qelbree |
| Kaleo, INC. | $114.46 | 2019-2022 | |
| Sanofi Pasteur INC. | $111.28 | 2023-2024 | |
| Pfizer INC. | $94.05 | 2023-2025 | |
| Glaxosmithkline, LLC. | $77.34 | 2020-2025 | Bexsero, Rotarix, Pediarix |
| Ironshore Pharmaceuticals INC. | $76.08 | 2023-2024 | Jornay Pm |
| Alk-Abello, INC | $74.32 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Cranial Technologies, INC | $53.40 | 2024-2025 | Doc Band |
| Neos Therapeutics, LP | $27.23 | 2019-2024 | Cotempla Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $16.89 | 2024 | Flumist Quadrivalent |
| Cumberland Pharmaceuticals, INC. | $14.54 | 2024 | Kristalose |
| Aytu Biopharma, INC. | $13.22 | 2022 | |
| Merck Sharp & Dohme LLC | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Pakonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.